Building An Oncology Business In China: Balancing Access And Pricing Freedom
The question facing many pharmaceutical companies is whether to pursue drug coverage through China's rapidly evolving health care reimbursement system or tap the fast expanding self-pay market. There's no one-size fits all answer, but understanding the nuances of the local market is essential to getting the strategy right.
You may also be interested in...
Medical device manufacturers are operating in what may be the industry’s most challenging business and regulatory environment in recent history, attorneys Bill McConagha and Pamela Amaechi argue in this guest article.
Biolife4D CEO dropped president title and Cryo-Cell International co-chief executive officer dropped director title to open spots for new executives; Essex Bio-Technology deputy managing director was promoted to executive director; and more.
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.